CERO THERAPEUTICS HLDGS INC
COM NEW · CUSIP 71902K303
0
institutional holders
-16 vs Q1 2025
—reported value*
0 new
0 added
0 reduced
16 sold out
net sold ≈ $527.7k (-723.1k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q2 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2024 | 1 |
| Q1 2025 | 16 |
| Q2 2025 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2025 | 15 | 1 |
| Q2 2025 | 0 | 16 |
Biggest buyers
| None |
Biggest sellers
| ARMISTICE CAPITAL, LLC | Sold out | -312.0k |
| Parallel Advisors, LLC | Sold out | -220.0k |
| Avantax Planning Partners, Inc. | Sold out | -74.3k |
| UBS Group AG | Sold out | -42.7k |
| ARCH Venture Management, LLC | Sold out | -22.1k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -16.9k |
| CITADEL ADVISORS LLC | Sold out | -16.2k |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Sold out | -13.3k |
| Tower Research Capital LLC (TRC) | Sold out | -5.0k |
| FNY Investment Advisers, LLC | Sold out | -262 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| ARMISTICE CAPITAL, LLC 13G · institution new · filed 2025-05-15 | 10.0% |
Holders, Q2 2025
| Manager | Shares | Change |
|---|